Pomerantz Law Firm Probes Investment Claims Against Immix Biopharma Amid Serious Allegations
Pomerantz LLP, a prominent law firm recognized for its expertise in corporate and securities litigation, has initiated an investigation focused on claims pertaining to Immix Biopharma, Inc. (NASDAQ: IMMX). This investigation is crucial for investors who believe their financial interests may have been adversely affected by possibly unlawful activities by the company and its leadership.
The matter gained traction following the abrupt appointment and subsequent termination of Richard Graydon as Chief Medical Officer. Initially welcomed into Immix in March 2026, Graydon's tenure was short-lived, culminating in a dismissal just four months later. The circumstances surrounding his exit have drawn significant media attention, particularly after revelations regarding his true identity. It was disclosed that Graydon was actually Ronald L. Fischer, a fugitive wanted for more than two decades in connection with serious criminal allegations. This shattering news broke on July 20, 2026, and immediately impacted Immix's market standing, leading to a considerable drop in their stock price by 14.15%. The company's share valuation fell from $10.25 to $8.80 per share on that very day.
Given these developments, the Pomerantz Law Firm is reaching out to investors of Immix Biopharma. They seek to ascertain the full scope of the allegations and determine if there are grounds for a class-action lawsuit based on potential securities fraud or violations of fiduciary duties. As the legal landscape evolves, those affected can become proactive by consulting with Pomerantz attorneys. Investors are urged to connect with Danielle Peyton from the firm at [email protected] or by phone at 646-581-9980, ext. 7980. Details regarding joining the class action can also be found through the firm's resources.
Pomerantz, which operates from multiple metropolitan areas including New York, Los Angeles, and London, has a longstanding reputation in seeking justice for victims of corporate misconduct. The firm was established by Abraham L. Pomerantz, known as a pioneer in class action law. Over the years, Pomerantz has successfully secured substantial compensations for its clients facing securities fraud and similar challenges. This current inquiry reflects the firm’s commitment to transparency and accountability in the corporate sector.
With the stakes involving Immix Biopharma becoming increasingly intense, this situation serves as a significant reminder for investors to remain vigilant regarding their investments. The gravity of the allegations against the company's officers has the potential to reshape the trust investors place in Immix, not to mention the surrounding biotech sector as a whole. As the investigations unfold, staying informed will be crucial for those with financial ties to the company. Knowledge is power in such scenarios, and investors must be prepared to take action if their interests are at risk.
The matter gained traction following the abrupt appointment and subsequent termination of Richard Graydon as Chief Medical Officer. Initially welcomed into Immix in March 2026, Graydon's tenure was short-lived, culminating in a dismissal just four months later. The circumstances surrounding his exit have drawn significant media attention, particularly after revelations regarding his true identity. It was disclosed that Graydon was actually Ronald L. Fischer, a fugitive wanted for more than two decades in connection with serious criminal allegations. This shattering news broke on July 20, 2026, and immediately impacted Immix's market standing, leading to a considerable drop in their stock price by 14.15%. The company's share valuation fell from $10.25 to $8.80 per share on that very day.
Given these developments, the Pomerantz Law Firm is reaching out to investors of Immix Biopharma. They seek to ascertain the full scope of the allegations and determine if there are grounds for a class-action lawsuit based on potential securities fraud or violations of fiduciary duties. As the legal landscape evolves, those affected can become proactive by consulting with Pomerantz attorneys. Investors are urged to connect with Danielle Peyton from the firm at [email protected] or by phone at 646-581-9980, ext. 7980. Details regarding joining the class action can also be found through the firm's resources.
Pomerantz, which operates from multiple metropolitan areas including New York, Los Angeles, and London, has a longstanding reputation in seeking justice for victims of corporate misconduct. The firm was established by Abraham L. Pomerantz, known as a pioneer in class action law. Over the years, Pomerantz has successfully secured substantial compensations for its clients facing securities fraud and similar challenges. This current inquiry reflects the firm’s commitment to transparency and accountability in the corporate sector.
With the stakes involving Immix Biopharma becoming increasingly intense, this situation serves as a significant reminder for investors to remain vigilant regarding their investments. The gravity of the allegations against the company's officers has the potential to reshape the trust investors place in Immix, not to mention the surrounding biotech sector as a whole. As the investigations unfold, staying informed will be crucial for those with financial ties to the company. Knowledge is power in such scenarios, and investors must be prepared to take action if their interests are at risk.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.